Logo image of CADL

CANDEL THERAPEUTICS INC (CADL) Stock Overview

USA - NASDAQ:CADL - US1374041093 - Common Stock

5.4 USD
+0.09 (+1.69%)
Last: 10/24/2025, 8:12:08 PM
5.4 USD
0 (0%)
After Hours: 10/24/2025, 8:12:08 PM

CADL Key Statistics, Chart & Performance

Key Statistics
Market Cap296.46M
Revenue(TTM)N/A
Net Income(TTM)-22136000
Shares54.90M
Float44.95M
52 Week High14.6
52 Week Low3.79
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-0.69
PEN/A
Fwd PEN/A
Earnings (Next)11-06 2025-11-06
IPO2021-07-27
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


CADL short term performance overview.The bars show the price performance of CADL in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -10 -20

CADL long term performance overview.The bars show the price performance of CADL in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 100 200 300 400 500

The current stock price of CADL is 5.4 USD. In the past month the price decreased by -2.53%. In the past year, price decreased by -3.57%.

CANDEL THERAPEUTICS INC / CADL Daily stock chart

CADL Latest News, Press Relases and Analysis

CADL Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 21.53 402.76B
AMGN AMGEN INC 13.38 157.07B
GILD GILEAD SCIENCES INC 15.63 150.06B
VRTX VERTEX PHARMACEUTICALS INC 24.88 108.04B
REGN REGENERON PHARMACEUTICALS 12.66 61.26B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 60.75B
ARGX ARGENX SE - ADR 88.74 50.32B
ONC BEONE MEDICINES LTD-ADR 5.02 34.14B
INSM INSMED INC N/A 33.75B
NTRA NATERA INC N/A 26.42B
BNTX BIONTECH SE-ADR N/A 25.40B
BIIB BIOGEN INC 9.36 21.98B

About CADL

Company Profile

CADL logo image Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. The company is headquartered in Needham, Massachusetts and currently employs 38 full-time employees. The company went IPO on 2021-07-27. CAN-2409 is the lead product candidate from the adenovirus platform. CAN-3110 is the lead product candidate from the herpes simplex virus (HSV) platform and is in an ongoing phase Ib clinical trial in recurrent high-grade glioma. Its enLIGHTEN Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. CAN-2409, Its advanced multimodal biological immunotherapy candidate, is an investigational, off-the-shelf, replication-defective adenovirus engineered to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to a patient’s specific tumor and induce an individualized, systemic immune response against the tumor.

Company Info

CANDEL THERAPEUTICS INC

117 Kendrick Street,, Suite 450

Needham MASSACHUSETTS US

CEO: Paul Peter Tak

Employees: 38

CADL Company Website

CADL Investor Relations

Phone: 16179165445

CANDEL THERAPEUTICS INC / CADL FAQ

Can you describe the business of CANDEL THERAPEUTICS INC?

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. The company is headquartered in Needham, Massachusetts and currently employs 38 full-time employees. The company went IPO on 2021-07-27. CAN-2409 is the lead product candidate from the adenovirus platform. CAN-3110 is the lead product candidate from the herpes simplex virus (HSV) platform and is in an ongoing phase Ib clinical trial in recurrent high-grade glioma. Its enLIGHTEN Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. CAN-2409, Its advanced multimodal biological immunotherapy candidate, is an investigational, off-the-shelf, replication-defective adenovirus engineered to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to a patient’s specific tumor and induce an individualized, systemic immune response against the tumor.


What is the current price of CADL stock?

The current stock price of CADL is 5.4 USD. The price increased by 1.69% in the last trading session.


Does CANDEL THERAPEUTICS INC pay dividends?

CADL does not pay a dividend.


What is the ChartMill technical and fundamental rating of CADL stock?

CADL has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


Can you provide the sector and industry classification for CANDEL THERAPEUTICS INC?

CANDEL THERAPEUTICS INC (CADL) operates in the Health Care sector and the Biotechnology industry.


How is the valuation of CANDEL THERAPEUTICS INC (CADL) based on its PE ratio?

CANDEL THERAPEUTICS INC (CADL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.69).


Would investing in CANDEL THERAPEUTICS INC be a good decision?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on CADL.


CADL Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

CADL Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to CADL. The financial health of CADL is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

CADL Financial Highlights

Over the last trailing twelve months CADL reported a non-GAAP Earnings per Share(EPS) of -0.69. The EPS increased by 59.27% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -20.89%
ROE -24.54%
Debt/Equity 0.01
Chartmill High Growth Momentum
EPS Q2Q%87.42%
Sales Q2Q%N/A
EPS 1Y (TTM)59.27%
Revenue 1Y (TTM)N/A

CADL Forecast & Estimates

12 analysts have analysed CADL and the average price target is 20.06 USD. This implies a price increase of 271.48% is expected in the next year compared to the current price of 5.4.


Analysts
Analysts81.67
Price Target20.06 (271.48%)
EPS Next Y74.2%
Revenue Next YearN/A

CADL Ownership

Ownership
Inst Owners42.29%
Ins Owners15.75%
Short Float %16.07%
Short Ratio9.22